Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein - PubMed (original) (raw)
Comparative Study
Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein
T J Matthews et al. Proc Natl Acad Sci U S A. 1986 Dec.
Abstract
By analogy to other retroviruses, the major envelope glycoprotein, gp120, of human T-lymphotropic virus type III (HTLV-III) is a probable target for neutralizing antibody. This antigen has been purified from H9 cells chronically infected with the HTLV-IIIB prototype strain. Several goats immunized with the gp120 produced antibodies that neutralized infection of H9 cells by the homologous virus isolate. These same sera failed to neutralize the divergent HTLV-IIIRF isolate. Individuals infected with HTLV-III commonly develop antibodies to gp120 that could be isolated by using the gp120 antigen coupled to an immunoadsorbent resin. The antibody fraction that bound tightly to such a resin was found to neutralize the IIIB but not the RF isolate in a similar fashion as the goat anti-gp120 sera. However, the nonbinding fraction (effluent) from the resin also contained neutralizing activity that was able to block infection by both virus isolates with similar efficacy. Human antibodies to the other virus envelope gene product, the transmembrane gp41, were also affinity purified by utilizing the recombinant peptide 121, but these failed to influence infection by either virus isolate.
Similar articles
- Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein.
Matthews TJ, Langlois AJ, Robey WG, Chang NT, Gallo RC, Fischinger PJ, Bolognesi DP. Matthews TJ, et al. Haematol Blood Transfus. 1987;31:414-22. doi: 10.1007/978-3-642-72624-8_89. Haematol Blood Transfus. 1987. PMID: 2832276 - Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
Goudsmit J, Debouck C, Meloen RH, Smit L, Bakker M, Asher DM, Wolff AV, Gibbs CJ Jr, Gajdusek DC. Goudsmit J, et al. Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478-82. doi: 10.1073/pnas.85.12.4478. Proc Natl Acad Sci U S A. 1988. PMID: 2454471 Free PMC article. - Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
Palker TJ, Clark ME, Langlois AJ, Matthews TJ, Weinhold KJ, Randall RR, Bolognesi DP, Haynes BF. Palker TJ, et al. Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932-6. doi: 10.1073/pnas.85.6.1932. Proc Natl Acad Sci U S A. 1988. PMID: 2450351 Free PMC article. - Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.
Palker TJ, Matthews TJ, Langlois A, Tanner ME, Martin ME, Scearce RM, Kim JE, Berzofsky JA, Bolognesi DP, Haynes BF. Palker TJ, et al. J Immunol. 1989 May 15;142(10):3612-9. J Immunol. 1989. PMID: 2469721 - Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III).
Fischinger PJ, Robey WG, Koprowski H, Gallo RC, Bolognesi DP. Fischinger PJ, et al. Cancer Res. 1985 Sep;45(9 Suppl):4694s-4699s. Cancer Res. 1985. PMID: 2410115 Review.
Cited by
- Characterization of treatment failure in HIV positive patients in the Colombian Caribbean region.
De La Hoz JM, Bolaño L, Cárdenas O, González R, Sabbag J, Palacio L, Alonso LM, San-Juan-Vergara H, Cervantes-Acosta G. De La Hoz JM, et al. Colomb Med (Cali). 2014 Dec 30;45(4):162-7. eCollection 2014 Oct-Dec. Colomb Med (Cali). 2014. PMID: 25767304 Free PMC article. - Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.
Totrov M, Jiang X, Kong XP, Cohen S, Krachmarov C, Salomon A, Williams C, Seaman MS, Abagyan R, Cardozo T, Gorny MK, Wang S, Lu S, Pinter A, Zolla-Pazner S. Totrov M, et al. Virology. 2010 Sep 30;405(2):513-23. doi: 10.1016/j.virol.2010.06.027. Epub 2010 Jul 21. Virology. 2010. PMID: 20663531 Free PMC article. - Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity.
Nishiyama Y, Planque S, Mitsuda Y, Nitti G, Taguchi H, Jin L, Symersky J, Boivin S, Sienczyk M, Salas M, Hanson CV, Paul S. Nishiyama Y, et al. J Biol Chem. 2009 Oct 30;284(44):30627-42. doi: 10.1074/jbc.M109.032185. Epub 2009 Sep 2. J Biol Chem. 2009. PMID: 19726674 Free PMC article. - Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.
Gorny MK, Williams C, Volsky B, Revesz K, Wang XH, Burda S, Kimura T, Konings FA, Nádas A, Anyangwe CA, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S. Gorny MK, et al. J Virol. 2006 Jul;80(14):6865-72. doi: 10.1128/JVI.02202-05. J Virol. 2006. PMID: 16809292 Free PMC article. - Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.
Nishimura Y, Igarashi T, Haigwood NL, Sadjadpour R, Donau OK, Buckler C, Plishka RJ, Buckler-White A, Martin MA. Nishimura Y, et al. Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15131-6. doi: 10.1073/pnas.2436476100. Epub 2003 Nov 19. Proc Natl Acad Sci U S A. 2003. PMID: 14627745 Free PMC article.
References
- Virology. 1976 May;71(1):169-84 - PubMed
- Proc Natl Acad Sci U S A. 1986 Sep;83(18):7023-7 - PubMed
- Cancer Res. 1982 Oct;42(10):3995-9 - PubMed
- Science. 1984 May 4;224(4648):497-500 - PubMed
- Nature. 1985 Jan 24-30;313(6000):277-84 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources